Register Login

Quick Question Archive

October 2025 QQ: Reporting Assay Uncertainty Data

Please refer to our August 29, 2025 discussion, “Hemostasis Assay Statistical Variation.” In this post, we linked the article, Mullier F, Gouin-Thibault I, Meijer P, et al. Time to integrate measurement uncertainty in method comparison and interpretation of hemostasis laboratory assays. Res Practice Thromb Hemost 2025: 9, https://doi.org/10.1016/j.rpth.2025.102993. The authors contend that we should report uncertainty […]
read more

July 2025 QQ: Hemophilia Rebalancing Therapy

Our July 2025 Quick Question asked, “Which is a hemophilia ‘rebalancing’ therapeutic?” The question attracted a modest 22 participants, perhaps an indication that rebalancing therapy was only FDA-approved in 2025 and awaits approval in Canada and Europe. Here are your responses… Valoctocogene roxaparvovec-rvox (ROCTAVIAN) 3 (14%) Efanesoctocog alfa (ALTUVIIIO) 1 (4%) Emicizumab (HemLibra) 7 (32%) […]
read more

July 2025 Quick Question: Hemophilia Therapeutics

At the June 21–25 ISTH meeting in Washington, DC, we heard several quality presentations describing the new hemophilia treatment materials, including updated EHL concentrates plus the bypassing, rebalancing, and gene transfer therapies. In follow-up, our July 2025 Quick Question asks you to select the choice that represents the recently approved rebalancing therapies. Please make your […]
read more